WeedLife News Network
Stanford Researchers Open Medical Cannabis Company with Oral Therapy for MS Pain, Spasticity as Lead Product - Cannabis News
A new medical cannabis company called Katexco Pharmaceuticals aims to develop oral therapies that harness the brain’s endocannabinoid and nicotine receptors to treat inflammatory diseases such as multiple sclerosis.
Co-founded by two Stanford University researchers — Jonathan Rothbard, PhD, and Lawrence Steinman, MD — Katexco will leverage their expertise in immunological therapy and use a synergistic approach to use the body’s natural system to curb inflammation.
In addition to multiple sclerosis, Katexco will work to treat gastrointestinal conditions such as Crohn’s disease, and gout.
Click here to read the complete article
Vijaya Iyer ~ Multiple Sclerosis News Today ~
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.
